Abstract

Autoimmune diseases pose significant challenges to patients and healthcare providers, characterized by dysregulated immune responses leading to chronic inflammation and tissue damage. Cytokines, key mediators of inflammation, play a central role in driving autoimmune pathology. In recent years, cytokine inhibitors have emerged as valuable therapeutic agents, offering targeted intervention to modulate immune responses and alleviate symptoms. This abstract provides an overview of the role of cytokine inhibitors in autoimmune disease management. By selectively targeting pro-inflammatory cytokines such as Tumor Necrosis Factor-Alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin-17 (IL-17), these inhibitors effectively suppress inflammation and halt disease progression. Clinical applications of cytokine inhibitors, including their use in rheumatoid arthritis, psoriasis, and inflammatory bowel disease, are highlighted. Despite challenges such as infection risk and treatment non-response, cytokine inhibitors represent a cornerstone in the management of autoimmune diseases, offering promising avenues for precision medicine and improved patient outcomes. Future research efforts focused on personalized approaches, novel therapeutic targets, and enhanced drug delivery systems hold promise for further advancing the field of cytokine inhibition in autoimmune disease management.